Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.

Abstract: A model-assisted system for identifying a group of patients for a cohort using a generalized biomarker model may include a processor programmed to provide, to a generalized biomarker model, a first biomarker associated with a cohort, the generalized biomarker model being trained based on one or more second biomarkers; receive, from the generalized biomarker model, an output indicating a plurality of individuals with associated likelihoods of at least one of: having an attribute associated with the third biomarker or having been tested for the attribute associated with the first biomarker; determine a likelihood threshold based on a predetermined cohort size associated with the first biomarker and identify, based on the output, a group of the plurality of individuals for inclusion in a cohort, each individual in the group of the plurality of individuals being associated with a likelihood received from the generalized biomarker model that satisfies the likelihood threshold.

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).

Abstract: A graphical user interface for displaying an electronic medical record associated with a patient is provided. The graphical user interface may include an area configured to display patient information, which may include at least a name of the patient. The graphical user interface may also include an indicator displayed in association with the name of the patient. The indicator may include information specifying that the patient is potentially eligible for one or more trials, the patient is participating in one or more trials, or the patient has completed one or more trials.

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

Abstract: A method for depositing particles on a surface includes receiving a plurality of particles, a particle of the plurality of particles having a polymer matrix conjugated to nucleic acid strands, exposing the plurality of particles to a solution; and applying the plurality of particles to a surface following exposing the plurality of particles to the solution, particles of the plurality of particles depositing on the surface. The solution includes a magnesium salt in a range of 30 mM to 500 mM and polyethylene glycol.

Abstract: Disclosed herein are shelf-stable formulations comprising benzoyl peroxide in a formulation effective to reduce or prevent degradation of the benzoyl peroxide to benzene. Further provided herein are methods of preventing or reducing degradation of benzoyl peroxide to benzene in a drug product, as well as methods of identifying drug products containing benzoyl peroxide that form high levels of benzene.

Abstract: Disclosed herein are shelf-stable formulations comprising benzoyl peroxide in a formulation effective to reduce or prevent degradation of the benzoyl peroxide to benzene. Further provided herein are methods of preventing or reducing degradation of benzoyl peroxide to benzene in a drug product, as well as methods of identifying drug products containing benzoyl peroxide that form high levels of benzene.

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).

Abstract: A graphical user interface for displaying an electronic medical record associated with a patient is provided. The graphical user interface may include an area configured to display patient information, which may include at least a name of the patient. The graphical user interface may also include an indicator displayed in association with the name of the patient. The indicator may include information specifying that the patient is potentially eligible for one or more trials, the patient is participating in one or more trials, or the patient has completed one or more trials.

Abstract: A method for depositing particles on a surface includes receiving a plurality of particles, a particle of the plurality of particles having a polymer matrix conjugated to nucleic acid strands, exposing the plurality of particles to a solution; and applying the plurality of particles to a surface following exposing the plurality of particles to the solution, particles of the plurality of particles depositing on the surface. The solution includes a magnesium salt in a range of 30 mM to 500 mM, a potassium salt in a range of 0.8 M to 1.0 M, a buffering agent in a range of 150 mM to 500 mM, and a surfactant in a range of 0.05% to 0.5%.

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).

Abstract: Embodiments are directed to low-profile, low-weight cargo loader, including a pair of cargo loaders including a first cargo loader arranged in tandem with a second cargo loader in a first orientation. According to an embodiment, each of the first cargo loader and the second cargo loader includes a chassis, a scissor lift, a platform, a front driving system, and a rear driving system. According to an embodiment, the second cargo loader is configured to be stacked on the first cargo loader in a second orientation.

Abstract: Embodiments are directed to an anti-rattle device, including a plurality of handle bracket assemblies, and a wedge assembly. Each of the handle bracket assemblies includes an adjustable handle, a bracket, and a threaded rod. The wedge assembly includes a frame and a rubber wedge. Each of the handle bracket assemblies is secured to a pallet. The adjustable handle of each of the handle bracket assemblies is configured to actuate to move the wedge assembly in a downward direction to engage a rail of a cargo handling system, such that the engagement of the wedge assembly against the rail creates tension and frictional force between the pallet and the cargo handling system to further secure the pallet in place.

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

Abstract: A method of forming a polymer matrix array includes applying an aqueous solution into wells of a well array. The aqueous solution includes polymer precursors. The method further includes applying an immiscible fluid over the well array to isolate the aqueous solution within the wells of the well array and polymerizing the polymer precursors isolated in the wells of the well array to form the polymer matrix array. An apparatus includes a sensor array, a well array corresponding to the sensor array, and an array of polymer matrices disposed in the well array.

Abstract: A method of forming a polymer matrix array includes treating a surface within a well of a well array with a surface compound including a surface reactive functional group and a radical-forming distal group; applying an aqueous solution including polymer precursors to the well of the well array; and activating the radical-forming distal group of the surface coupling compound with an initiator and atom transfer radical polymerization (ATRP) catalyst to initiate radical polymerization of the polymer precursors within the well of the well array to form the polymer matrix array.

Abstract: A model-assisted system for identifying a group of patients for a cohort using a generalized biomarker model may include a processor programmed to provide, to a generalized biomarker model, a first biomarker associated with a cohort, the generalized biomarker model being trained based on one or more second biomarkers; receive, from the generalized biomarker model, an output indicating a plurality of individuals with associated likelihoods of at least one of: having an attribute associated with the third biomarker or having been tested for the attribute associated with the first biomarker; determine a likelihood threshold based on a predetermined cohort size associated with the first biomarker and identify, based on the output, a group of the plurality of individuals for inclusion in a cohort, each individual in the group of the plurality of individuals being associated with a likelihood received from the generalized biomarker model that satisfies the likelihood threshold.

Abstract: The disclosure relates to novel particle compositions and methods of making said compositions having applications in nucleic acid analysis, as well as apparatuses and systems for the same.